The dysregulation of the cell cycle can support breast cancer growth, and the blockade of cyclin-dependent kinase (CDK)4/6 with the inhibitor palbociclib has demonstrated a clinical benefit for advanced ER+ breast cancer [19]. The gene discussed is CDK4; the disease is breast carcinoma.